New Rochelle, NY, United States of America

Anthony A Sauve

This inventor holds 26 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 5 EPO patents, primarily in Nicotinamide Research. Top assignees: Cornell University, Albert Einstein College of Medicine, Duke University. Active years: 2006-2025.

USPTO Granted Patents = 26 (Patent Applications = 1)

% Patents Active = 92.3

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 2.1

ph-index = 4

Forward Citations = 141(Granted Patents)

Location History:

Bronx, NY (US) (2006 - 2014)
New Rochelle, NY (US) (2015 - 2024)

Company Filing History:

Albert Einstein College of Medicine

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

Areas of Expertise:

HCN1 Antagonists

Nicotinamide Mononucleotide

Riboside Compositions

Sirtuin Activators

Dihydronicotinamide

Beta-Nicotinate Ester

Heart Failure Treatment

Hearing Loss

ADP-Ribosyl Transferases

SIRT5

SIRT6

SIR2 Regulation

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12274679 - Substituted alkylphenols as HCN1 antagonists (2025-04-14),

2. 11926644 - Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives (2024-03-12),

3. 11684590 - Substituted alkylphenols as HCN1 antagonists (2023-06-27),

4. 11633414 - Nicotinoyl riboside compositions and methods of use (2023-04-25),

5. 11530233 - Beta-nicotinate ester nucleotides and processes for preparing same (2022-12-20),

6. 11098076 - Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives (2021-08-24),

7. 11077129 - Nicotinoyl riboside compositions and methods of use (2021-08-03),

8. 11028118 - Efficient synthesis of nicotinamide mononucleotide (2021-06-08),

9. 10961268 - β-nicotinate ester nucleotides and process for preparing same (2021-03-30),

10. 10668096 - Nicotinoyl riboside compositions and methods of use (2020-06-02),

11. 10590160 - Efficient synthesis of nicotinamide mononucleotide (2020-03-17),

12. 10525070 - Method of treating heart failure (2020-01-07),

13. 10392414 - Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives (2019-08-27),

14. 10206940 - Nicotinoyl riboside compositions and methods of use (2019-02-19),

15. 9861651 - Use of nicotinamide riboside to treat hearing loss (2018-01-09),

Title: Anthony A. Sauve: Innovator in Biomedical Research and Patenting

Introduction: Anthony A. Sauve, based in New Rochelle, NY, is a distinguished inventor with an impressive portfolio of 25 patents. His work primarily focuses on advancements in biomedical research, particularly in the fields of cellular biology and pharmacology.

Latest Patents: Among his latest innovations, Sauve has developed methods involving dihydronicotinamide riboside derivatives. This patent reveals a compound designed to enhance mammalian cell NAD production and improve mitochondrial cell densities. Another significant patent pertains to the use of substituted alkylphenols as HCN1 antagonists, providing novel compounds that modulate HCN channels involved in heart and brain function. These advancements have the potential to contribute greatly to treatments for HCN-related disorders, such as pain.

Career Highlights: Throughout his career, Sauve has held positions at renowned institutions like Cornell University and the Albert Einstein College of Medicine of Yeshiva University. His work at these prominent research centers has allowed him to make substantial contributions to the field of biomedical innovation.

Collaborations: Anthony A. Sauve has collaborated with notable colleagues, including Tianle Yang Redanz and Vern L Schramm. These partnerships have facilitated significant advancements in his research initiatives and have emphasized the importance of teamwork in the pursuit of scientific breakthroughs.

Conclusion: With a robust history of patents and research collaborations, Anthony A. Sauve exemplifies the spirit of innovation in the biomedical sector. His contributions continue to push the boundaries of our understanding in cell biology and therapeutic methods, marking him as a significant figure in contemporary scientific research.